DB15809ExperimentalProtein Based Therapies
CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant. As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in... As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens (RPCEC00000313).
- Mechanism
- Curator reviewed
Pharmacologically active on Apolipoprotein A-I
- Also known as
- CIGB-258
- Code names
- CIGB-258 peptide
Resolves to
Targets
What you can answer from here — as of July 08, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with CIGB-258 peptide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account